See more : Taiwan Hon Chuan Enterprise Co., Ltd. (9939.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Rigel Pharmaceuticals, Inc. (RIGL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rigel Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Nihon Tokushu Toryo Co., Ltd. (4619.T) Income Statement Analysis – Financial Results
- INTLOOP Inc. (9556.T) Income Statement Analysis – Financial Results
- Gem Spinners India Limited (GEMSPIN.BO) Income Statement Analysis – Financial Results
- FuelCell Energy, Inc. (FCELB) Income Statement Analysis – Financial Results
- Flowtech Fluidpower plc (FLO.L) Income Statement Analysis – Financial Results
Rigel Pharmaceuticals, Inc. (RIGL)
About Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 116.88M | 120.24M | 149.24M | 108.62M | 59.29M | 44.51M | 4.48M | 20.38M | 28.90M | 8.25M | 7.15M | 2.25M | 4.75M | 125.00M | 750.00K | 0.00 | 12.60M | 33.47M | 16.53M | 4.73M | 11.06M | 15.79M | 15.30M | 13.22M | 8.98M |
| Cost of Revenue | 7.11M | 1.75M | 1.08M | 895.00K | 906.00K | 287.00K | 46.27M | 63.45M | 62.83M | 67.70M | 75.33M | 78.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -7.56M | -1.91M |
| Gross Profit | 109.77M | 118.49M | 148.15M | 107.73M | 58.38M | 44.22M | -41.79M | -43.06M | -33.93M | -59.45M | -68.18M | -76.53M | 4.75M | 125.00M | 750.00K | 0.00 | 12.60M | 33.47M | 16.53M | 4.73M | 11.06M | 15.79M | 15.30M | 20.78M | 10.89M |
| Gross Profit Ratio | 93.92% | 98.55% | 99.27% | 99.18% | 98.47% | 99.36% | -931.87% | -211.27% | -117.43% | -720.56% | -953.54% | -3,401.24% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 157.17% | 121.22% |
| Research & Development | 24.52M | 60.27M | 65.24M | 60.10M | 52.89M | 46.90M | 46.27M | 63.45M | 62.83M | 67.70M | 75.33M | 78.78M | 69.35M | 64.39M | 90.74M | 109.67M | 70.36M | 56.97M | 52.04M | 48.52M | 43.36M | 43.35M | 32.31M | 32.03M | 17.11M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 70.00M | 37.83M | 20.91M | 17.81M | 31.80M | 19.61M | 22.85M | 21.77M | 25.29M | 20.90M | 27.04M | 21.76M | 19.55M | 12.41M | 13.08M | 8.52M | 9.45M | 7.95M | 6.69M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 105.74M | 112.45M | 91.89M | 76.60M | 74.59M | 70.00M | 37.83M | 20.91M | 17.81M | 31.80M | 19.61M | 22.85M | 21.77M | 25.29M | 20.90M | 27.04M | 21.76M | 19.55M | 12.41M | 13.08M | 8.52M | 9.45M | 7.95M | 6.69M | 3.95M |
| Other Expenses | 0.00 | 1.32M | 3.52M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.56M | 1.91M |
| Operating Expenses | 130.26M | 172.72M | 157.13M | 136.70M | 127.47M | 116.91M | 84.10M | 84.35M | 80.64M | 99.50M | 94.94M | 101.63M | 91.12M | 89.68M | 111.65M | 136.71M | 92.13M | 76.52M | 64.45M | 61.60M | 51.88M | 52.80M | 40.26M | 46.28M | 22.97M |
| Cost & Expenses | 137.37M | 174.47M | 158.21M | 137.59M | 128.38M | 117.19M | 84.10M | 84.35M | 80.64M | 99.50M | 94.94M | 101.63M | 91.12M | 89.68M | 111.65M | 136.71M | 92.13M | 76.52M | 64.45M | 61.60M | 51.88M | 52.80M | 40.26M | 38.72M | 21.06M |
| Interest Income | 2.27M | 684.00K | 47.00K | 582.00K | 2.53M | 2.20M | 892.00K | 437.00K | 222.00K | 243.00K | 442.00K | 537.00K | 420.00K | 303.00K | 600.00K | 4.44M | 5.48M | 5.70M | 2.94M | 966.00K | 374.00K | 856.00K | 1.96M | 1.08M | 0.00 |
| Interest Expense | 6.87M | 3.71M | 4.86M | 1.35M | 335.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.00K | 17.00K | 25.00K | 91.00K | 203.00K | 160.00K | 221.00K | 290.00K | 276.00K | 324.00K | 575.00K | 870.00K | 802.00K | 933.00K | 0.00 |
| Depreciation & Amortization | 1.24M | 998.00K | 1.16M | 706.00K | 683.00K | 594.00K | 465.00K | 941.00K | 1.44M | 2.36M | 2.59M | 2.43M | 1.96M | 1.32M | 1.40M | 1.43M | 1.34M | 1.42M | 1.18M | 2.37M | 3.18M | 5.82M | 6.76M | 7.56M | 1.91M |
| EBITDA | -16.98M | -53.87M | -11.29M | -27.69M | -65.88M | -69.89M | -77.53M | -63.03M | -50.30M | -88.89M | -85.20M | -96.94M | -83.99M | 39.30M | -110.03M | -130.85M | -79.53M | -43.05M | -47.92M | -54.49M | -37.65M | -31.19M | -18.20M | -17.95M | -10.17M |
| EBITDA Ratio | -14.53% | -44.53% | -5.98% | -26.14% | -112.26% | -163.30% | -1,791.88% | -285.97% | -179.27% | -1,107.24% | -1,185.40% | -4,416.76% | -1,768.27% | 29.55% | -14,519.07% | 0.00% | -620.50% | -124.37% | -282.84% | -1,150.73% | -339.04% | -197.57% | -118.93% | -135.78% | -113.25% |
| Operating Income | -20.49M | -54.23M | -8.98M | -28.97M | -69.09M | -72.68M | -79.62M | -69.74M | -51.74M | -91.25M | -89.47M | -99.38M | -86.37M | 35.32M | -112.04M | -136.71M | -79.53M | -43.05M | -47.92M | -56.87M | -40.83M | -37.02M | -24.96M | -25.51M | -12.08M |
| Operating Income Ratio | -17.53% | -45.10% | -6.01% | -26.67% | -116.53% | -163.30% | -1,775.56% | -342.15% | -179.07% | -1,106.05% | -1,251.31% | -4,416.76% | -1,818.27% | 28.25% | -14,938.27% | 0.00% | -631.17% | -128.60% | -289.98% | -1,201.50% | -369.31% | -234.46% | -163.11% | -192.96% | -134.46% |
| Total Other Income/Expenses | -4.60M | -3.02M | -4.81M | -771.00K | 2.20M | 2.20M | 1.62M | 525.00K | 279.00K | 341.00K | 442.00K | 537.00K | 395.00K | 2.57M | 397.00K | 4.28M | 5.26M | 5.41M | 2.67M | 612.00K | -370.00K | -14.00K | 1.16M | 145.00K | 0.00 |
| Income Before Tax | -25.09M | -58.57M | -17.31M | -29.74M | -66.89M | -70.48M | -77.99M | -69.22M | -51.46M | -90.91M | -89.03M | -98.84M | -85.97M | 37.89M | -111.64M | -132.44M | -74.27M | -37.64M | -45.26M | -56.26M | -41.20M | -37.03M | -23.81M | -25.36M | 0.00 |
| Income Before Tax Ratio | -21.47% | -48.71% | -11.60% | -27.38% | -112.83% | -158.35% | -1,739.34% | -339.58% | -178.11% | -1,101.92% | -1,245.13% | -4,392.89% | -1,809.96% | 30.31% | -14,885.33% | 0.00% | -589.46% | -112.44% | -273.85% | -1,188.57% | -372.65% | -234.55% | -155.56% | -191.86% | 0.00% |
| Income Tax Expense | 0.00 | 3.02M | 605.00K | 647.00K | -348.00K | 2.20M | -2.09M | 4.30M | -1.72M | -2.70M | 0.00 | -2.43M | 420.00K | 91.00K | -93.00K | -89.00K | 0.00 | 0.00 | 0.00 | -612.00K | 370.00K | 0.00 | 0.00 | 0.00 | 286.00K |
| Net Income | -25.09M | -61.60M | -17.91M | -30.39M | -66.55M | -70.48M | -77.99M | -69.22M | -51.46M | -90.91M | -89.03M | -98.84M | -85.97M | 37.89M | -111.55M | -132.35M | -74.27M | -37.64M | -45.26M | -56.26M | -41.20M | -37.03M | -23.81M | -25.36M | -12.37M |
| Net Income Ratio | -21.47% | -51.23% | -12.00% | -27.98% | -112.24% | -158.35% | -1,739.34% | -339.58% | -178.11% | -1,101.92% | -1,245.13% | -4,392.89% | -1,809.96% | 30.31% | -14,872.93% | 0.00% | -589.46% | -112.44% | -273.85% | -1,188.57% | -372.65% | -234.55% | -155.56% | -191.86% | -137.64% |
| EPS | -1.44 | -3.40 | -1.05 | -1.76 | -4.00 | -4.39 | -6.17 | -7.33 | -5.82 | -10.37 | -10.20 | -1.32 | -1.36 | 0.73 | -2.73 | -3.67 | -2.57 | -1.51 | -2.07 | -3.12 | -3.62 | -66.73 | -5.75 | -31.43 | -355.49 |
| EPS Diluted | -1.44 | -3.40 | -1.05 | -1.76 | -4.00 | -4.39 | -6.17 | -7.33 | -5.82 | -10.37 | -10.20 | -1.32 | -1.36 | 0.72 | -2.73 | -3.67 | -2.57 | -1.51 | -2.07 | -3.12 | -3.62 | -66.73 | -5.75 | -31.43 | -355.49 |
| Weighted Avg Shares Out | 17.40M | 17.24M | 17.05M | 16.88M | 16.72M | 16.05M | 12.63M | 9.44M | 8.84M | 8.77M | 8.73M | 74.88M | 63.33M | 52.06M | 40.88M | 36.03M | 28.94M | 24.94M | 21.86M | 18.05M | 11.40M | 554.94K | 4.14M | 806.92K | 34.79K |
| Weighted Avg Shares Out (Dil) | 17.40M | 17.24M | 17.05M | 16.88M | 16.74M | 16.05M | 12.63M | 9.44M | 8.84M | 8.77M | 8.73M | 74.97M | 63.33M | 52.57M | 40.88M | 36.03M | 28.94M | 24.94M | 21.86M | 18.05M | 11.40M | 554.94K | 4.14M | 806.92K | 34.79K |
Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®
Rigel Pharmaceuticals: Looking For More Growth
Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel (RIGL) Surges 19.7%: Is This an Indication of Further Gains?
Rigel to Present at the 2024 Cantor Global Healthcare Conference
Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML
Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan
Rigel to Participate in Upcoming September Investor Conferences
Rigel Pharmaceuticals, Inc. (RIGL) Q2 2024 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports